77 0

The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate

Title
The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate
Author
고성호
Keywords
Amyotrophic lateral sclerosis; Prognostic factors; Neurotrophic factors; Mesenchymal stromal cells
Issue Date
2012-01
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
Citation
EXPERIMENTAL NEUROLOGY; JAN 2012, 233 1, p472-p480, 9p.
Abstract
Amyotrophic lateral sclerosis (ALS) is caused by motor neuron death. The relationship between the prognosis of ALS patients and the function of their bone marrow mesenchymal stromal cells (BM-MSCs) is unclear. We designed this study to assess the correlation between the progression rate of the ALS Functional Rating Scale-revised version (Delta FS), which is reported to predict prognosis, and the pluripotency and trophic factor secreting capacity of ALS patients' BM-MSCs. We evaluated Delta FS in 23 ALS patients and isolated BM-MSCs from those patients and five healthy people. Levels of Nanog, Oct-4, and Nestin mRNA were examined to evaluate pluripotency, and levels of BDNF, ECGF1, bFGF-2, HGF, IGF-1, PGF, TGF-1 beta, SDF-1 alpha, GDNF, VEGF, and ANG mRNA were examined to assess trophic factor secreting capacity. In addition, we measured the protein levels of Nanog, Oct-4, Nestin, SDF-1 alpha, ANG, bFGF-2, VEGF, IGF-1, GDNF, and BDNF. mRNA levels of Nanog, Oct-4, ECGF1, bFGF-2, HGF, IGF-1, PGF, TGF-1 beta, SDF-1 alpha, GDNF. VEGF, and ANG were negatively correlations with Delta FS. However, those of Nestin and BDNF were not significantly correlated with Delta FS. Similarly, Nanog, Oct-4, SDF-1 alpha, ANG, bFGF-2, VEGF, IGF-1, and GDNF protein levels had a significant negative correlation with Delta FS. Results indicate that the pluripotency and trophic factor secreting capacity of the BM-MSCs of ALS patients are reduced in proportion to a poorer prognosis. We therefore suggest that healthy allogeneic BM-MSCs might be a better option for cell therapy in ALS patients. (C) 2011 Elsevier Inc. All rights reserved.
URI
https://www.sciencedirect.com/science/article/pii/S0014488611004250http://hdl.handle.net/20.500.11754/37555
ISSN
0014-4886
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE